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Acute kidney injury (AKI) independently increases morbidity and mortality in children admitted to the hospital. Renal replace-
ment therapy (RRT) is an essential therapy in the setting of AKI and ﬂuid overload. The decision to initiate RRT is complex and
oftencomplicated byconcernsrelated to patienthemodynamicandthermodynamicinstability.ThechoiceofwhichRRT modality
to use depends on numerous criteria that are both patient and treatment center speciﬁc. Surprisingly, despite decades of use, no
randomized, controlled trial study involving RRT in pediatrics has been performed. Because of these factors, clear-cut consensus
is lackingregarding keyquestions surrounding RRT delivery. In thispaper, we willsummarizeexisting data concerningRRT usein
children. We discuss the major modalities and the data-driven speciﬁcs of each, followed by controversies in RRT. As no standard
ofcare is in widespread use for RRT in AKI or in multiorgan disease, we concludein this paper thatprospective studies of RRT are
needed to identify best practice guidelines.
1.Introduction
Acute kidney injury (AKI) aﬀects a signiﬁcant proportion of
critically ill children. Using a revised AKI deﬁnition, a recent
study indicated that up to 10% of all children admitted to
the pediatric intensive care unit (PICU) suﬀer some degree
of kidney injury [1]. The kidney is central to numerous
homeostatic mechanisms in the body including: (1) ﬂuid
balance, (2) acid-base balance, (3) erythropoiesis, and (4)
vascular tone regulation. Aberrancies in kidney function,
therefore, can negatively aﬀect host survival. AKI is often
recognized as a complication of multi-organ disease and
independentlyincreasestheriskofmortality[2,3].Although
formal and deﬁnite indications for use are lacking, RRT is
employed for AKI, ﬂuid overload, and sepsis. While revised
deﬁnitions of AKI have aided in stratiﬁcation of injury se-
verity [4–6], controversy and uncertainty surrounds the use
of RRT. It is unclear which patients are appropriate for
therapy, which modalities should be used, what the triggers
are for initiation, what “dose” should be prescribed, and how
long treatment should continue.
The Prospective Pediatric Continuous Renal Replace-
ment Therapy (ppCRRT) registry, a comprehensive and
collaborative registry composed of thirteen select pediatric
referral centers,wasestablishedin2000toprospectivelyeval-
uate clinical aspects of CRRT and recently reported an
overall mortality of 43.1% for critically ill children placed on
RRT [7]. This statistic underscores the need for urgent and
broad-based prospective study of children placed on RRT.
In this paper, we will lay a framework for understanding the
rationale for RRT initiation, investigate the evidence for use
of speciﬁc RRT modalities (Table 1), outcomes using these
modalities, and also establish a purpose statement for the
future of RRT study.
2.The DifferentModalitiesofRenal
ReplacementTherapy
2.1. Peritoneal Dialysis. Peritoneal dialysis (PD) is the most
widely available form of renal replacement therapy used in
children. Almost all centers that care for acutely ill children2 International Journal of Nephrology
Table 1: Comparison of peritoneal dialysis (PD), intermittent hemodialysis (IHD), and continuous renal replacement therapies (CRRT).
Variable PD IHD CRRT
Continuous therapy Yes No Yes
Hemodynamic stability Yes No Yes
Fluid balance achieved Yes/No, Cycle dependent Yes/No, Intermittent Yes, pump controlled
Ease of use Yes No No
Adequate nutrition delivery variable variable Yes
Solute control Yes Yes Yes
Ultraﬁltration control Variable Yes Yes
Anticoagulation No Yes Yes
Acute ingestion removal No Yes Variable
Continuous toxin removal Variable No Yes
ICU nursing needs Low High High
Patient mobility No Yes No
Cost Low High High
Vascular access need No Yes Yes
Infection potential Yes Yes Yes
Use in inborn-errors of metabolism No Yes Yes
Adapted with permission from Walters et al. [8].
are capable of incorporating this technique into practice. PD
is especially important for developing countries with limited
resources.
Pro. The beneﬁts of peritoneal dialysis include ease and
quickness of catheter insertion, inexpensive cost compared
to other modalities, and general tolerance with regards to
hemodynamic stability. Percutaneously placed intraperito-
neal catheters or permanent Tenckhoﬀ catheters are used
even in neonates, and catheter placement is relatively simple
compared to the vascular access required for intermittent
hemodialysis (IHD) or continuous renal replacement ther-
apy(CRRT).Duetoeaseoftolerance,PDcathetershavebeen
prophylactically placed in neonates after cardiopulmonary
bypass surgery felt to be at high risk for ischemic kidney
injury [9]. Of global importance, particularly for areas with
little technologic ability, PD can be performed manually and
does not require a cycling device. Peritoneal dialysis ﬂuid,
either lactate based (USA) or bicarbonate based (outside
USA), is nearly universally available. A major advantage of
PDisabsence ofa need foranticoagulation.Functionally, PD
isideallysuitedforpatientsthathavemoderateillnessandare
poorcandidatesformodalitieswhichrequireanticoagulation
or large vascular access.
Con. Due to its relatively low clearance compared to IHD
and CRRT, PD is ill suited for situations such as acute toxin
ingestions, severe metabolic disturbances [10]. In cases of
tremendous ﬂuid overload, the rate of ﬂuid removal of PD
may not be rapid enough to prevent subsequent injury and
morbidity. Manual PD can be labor intensive for the bedside
practitioner, especially if the cycle frequency is high. Also,
PD cannot be used in children with congenital abdomi-
nal malformations such as omphalocele, gastroschisis, and
bladder exstrophy, or in patients with signiﬁcant abdominal
adhesions.
Evidence. Though rates of PD use have decreased in the
PICU, it is still the most commonly used method of RRT
in children in the world [11]. The use of PD is favored in
the neonates who often have diﬃcult vascular access, low
tolerance to volume shifts, and thermodynamic instability
[12]. In neonates with heart failure, PD provides a safe and
adequate strategy for children and allows reasonable crea-
tinine clearance rates [13]. The use of peritoneal dialysis is
documented in children following cardiopulmonary bypass;
Sorof et al. report no deaths or adverse hemodynamic eﬀects
during PD in 20 consecutive children immediately after car-
diopulmonary bypass (CPB) [9, 13–17]. In a single center
study, survivors after CPB had a shorter interval between
the diagnosis of AKI and PD initiation than nonsurvivors
(1.2+0 .4d a y sv e r s u s4 .3+1 .2d a y s )[ 17]. Numerous other
reports demonstrate the safety and eﬃcacy of PD after
cardiopulmonary bypass including providing eﬀective dia-
lytic eﬃciency measurements (Kt/V > 2.1, where K is the
clearance of urea, t is the time of dialysis, and V is a patient’s
total body water; goal for PD is >2.0/week) [15–19].
Opinion. PD is the most often used form of RRT in adults
and children worldwide, owing to cost and ease of use [20].
In skilled hands, PD is highly eﬀective at removing solute
and ﬂuid and can be tailored to patient needs. Practitioners
should be mindful ofthe potential forPD if vascular catheter
placementisproblematic.Thismodalitydoesnotrequirean-
ticoagulation and is ideal for neonates, children with inade-
quate vascular access, and children who can tolerate slower
ﬂuid removal and electrolyte correction.International Journal of Nephrology 3
2.2. Intermittent Hemodialysis. Intermittent hemodialysis
(IHD) use requires center selective criteria of technical ex-
pertise and trained personnel and patient selective criteria of
hemodynamic stability and vascular access.
Pro. T h eu s eo fI H Di si d e a lf o ra c u t ep r e s e n t a t i o n so fr e n a l
dysfunction or electrolyte imbalance. Because it oﬀers the
highest dose of dialysis in the shortest time frame, IHD is
perfectly suited for disease processes which cause acute dis-
ruptions in homeostasis such as drug ingestions, tumor lysis
syndrome, and hyperammonemia. Additionally, it allows for
isolated ultraﬁltration and titration of dialysis ﬂuid solute
concentration to correct metabolic disturbances such as hy-
pernatremia. IHD is time limited, allowing for patient mo-
bility, for example, to travel if needed for other diagnostic
tests or procedures. In centers where continuous RRT is not
available, some IHD machines permit slower and extended
dialysis (SLED) which allows for gradual removal of solute
and/or ﬂuid [21].
Con. The technical requirements of IHD represent a major
challenge to its use. IHD use is limited by thetrained person-
nel available at a given medical care center and by the techni-
cal support availableif trouble arises. Secondly,IHDrequires
vascular access in a large vessel. Though performed, this is
especially problematicinchildren forwhom obtaining access
isachronicproblem[22].Neonatesmaybeunabletotolerate
IHD simply because of inability to oﬀer an appropriate can-
nula size to maintain adequate ﬂow rates. Additionally, large
IHD catheter placement can lead to vascular damage such as
stenosis and thrombosis. Many nephrologists feel that for
thisreason,thesubclavianveinsshouldbeavoidedaltogether
[8]. Future chronic dialysis access needs may be greatly im-
peded by placement of temporary IHD catheters [23]. IHD
use causes large volume shifts and may be unfeasible in pa-
tients that are hemodynamically unstable and those, such
as small infants, who do not tolerate the volume shifts that
occur during dialysis. Disequilibrium syndrome, secondary
torapid osmolarshifts, may complicatehemodialysisleading
to seizures and cerebraledema, butit can be oﬀset with short
dialytic runs or with small doses of mannitol [24]. IHD
requires anticoagulation, most commonly with heparin
(althoughlow-molecular-weightheparins andthealternative
anticoagulants danaparoid, lepirudin, and citrate can be
used in patients with heparin-induced thrombocytopenia).
Finally,becauseitistimelimited,IHDusedoesnotlessen the
ﬂuidrestrictions thatareoftenplacedoncriticallyillpatients.
Thus, using IHD requires diligent daily planning to balance
UF with goal ﬂuids, including boluses and blood products,
and nutrition.
Evidence. Prior to the rise in popularity of continuous renal
replacement therapy, intermittent hemodialysis was the
modality of choice in patients requiring aggressive support
for acute kidney injury. Other than for acute ingestions and
electrolyte disturbances, the use of IHD has taken a back-
seat to CRRT in the intensive care setting requiring solute
and ﬂuid control. The adult SHARF 4 trials (Stuivenberg
Hospital AcuteRenal Failure), however, found no diﬀerences
inmortalityorrenalrecoveryin316adultswithAKIbetween
IHD and CRRT [25]. Similarly, a meta-analysis of 43 studies
comparing IHD to CRRT in adults reports that CRRT does
not oﬀer an advantage with regard to survival or long term
dialysis dependence [26]. Pediatric data comparing IHD to
other modalities in AKI is limited. In 2001, Bunchman et al.
published data on 226 children receiving RRT. In this study,
81% of the 61 children receiving IHD survived compared
to only 40% for hemoﬁltration; however, the former group
received signiﬁcantly less vasopressor support than the latter
[27]. Retrospectively, the survival of pediatric AKI for IHD
(73–89%) has been higher than those for CRRT (34–58%)
[27].
Opinion. Intermittent hemodialysis is eﬀective therapy for
acuteingestions, toxins, and ﬂuidoverload. IHD carries risks
for line placement, technical diﬃculty in small patients and
neonates, and complications with rapid shifts in ﬂuids and
electrolytes. IHD is ideal for patients with acute electrolyte
abnormalities and those that would beneﬁt from and can
tolerate high doses of dialysis in a short time frame [28].
2.3. Continuous Renal Replacement Therapy. The use of
continuous dialysis for AKI is widespread in PICUs. Arterio-
venous hemoﬁltration was ﬁrst described in the late 1970s
and the 1980s, including in infants [29]. CRRT became
popular in pediatric AKI in part because venovenous ﬁltra-
tion machines, which oﬀset the need for patient perfusion-
pressure-driven ultraﬁltrate, eased the problem of low driv-
ing pressures in pediatric patients. Additionally, advances in
CRRT technology allowed gravimetric and volumetric con-
trol of hemoﬁltration to allow for accurate ultraﬁltration
ﬂows [30]. Still, while CRRT use expands, in both adults
and pediatrics the risk-beneﬁt ratio pits known risks to the-
oretical beneﬁts. A major limitation to the standardization
of CRRTuse is the lack of prospective randomized data from
controlled studies, evaluating the time of initiation, route of
delivery, and eﬃcacy. Retrospective data attempts to answer
some of these questions.
Pro. The major advantage of CRRT is that it aﬀords nearly
continuous adjustment of ultraﬁltration. This feature makes
it well suited for patients with hemodynamic instability
[31, 32]. CRRT (and IHD) allows for ultraﬁltration to be
independently regulated from solute removal. This confers
great beneﬁt for patients with sensitive electrolyte needs and
ﬂuid states. Finally, ﬂuid delivery doesnot require restriction
while CRRT is in use, aﬀording increased freedom for nutri-
tion. The preferred modalities of CRRT in children are likely
aﬀected by site-speciﬁc familiarity and local preference, and
data are retrospective [8, 22, 31, 33].
Con. The primary drawback to CRRT use is its complexity.
The level of technical expertise required is high and, as
such, is not available at many centers worldwide. The need
for vascular access can often complicate its use. Attaining
adequate ﬂow rates in neonates and small children can be4 International Journal of Nephrology
Table 2: Ideal Catheter size and patient size for CRRT.
Patient size Catheter size Site of insertion
Neonate 7 Fr IJ/EJ, femoral
3–6 kilogram 7 Fr IJ/EJ, femoral
6–10 kilogram 8 Fr IJ/EJ, subclav, femoral
>10–20 kilogram 9 Fr IJ/EJ, subclav, femoral
>20–30 kilogram 10 Fr IJ/EJ, subclav, femoral
>30 kilogram 12 Fr IJ/EJ, subclav, femoral
Fr: French; IJ: internal jugular vein; EJ: external jugular vein; subclav:
subclavian vein. Adapted with permission from Goldstein [34].
diﬃcult even despite recommended catheter size placement
(Table 2). As in IHD, CRRT in small patients is complicated
by the fact that a large percentage (10–15%) of blood vol-
ume may be extracorporeal at any given time. This amount
of volume shift can lead to a high amount of thermody-
namic instability. Bradykinin release syndrome (hypoten-
sion, mucosal congestion, and bronchospasm upon contact
of patient blood with a hemoﬁlter) is a problem with
CRRT in infants using an AN-69 membrane circuit. Finally,
anticoagulation may pose added complications to patients
in septic shock and disseminated intravascular coagulation
(DIC).
Evidence. CRRT oﬀers minute to minute control of ultraﬁl-
trate and aﬀords practitioners the ﬂexibility to use volume
intense medications, blood products, and nutrition. CRRT
oﬀers better control of uremia compared to PD or IHD [35]
and allows practitioners to control solute levels to targets,
which is critical in cases such as children with increased
intracranial pressure who require tight control of serum
osmolarity [36]. However, no prospective study of CRRT
exists in either the adult or the pediatric literature. Also,
no controlled trial comparing the eﬃcacy of PD to IHD to
CRRT in pediatrics exists. A study comparing PD to CRRT
demonstrated a signiﬁcant survival diﬀerence with CRRT
(85%) versus PD (43%), but critics have indicated that rigid
tubing, manually exchanged ﬂuid, and hyperglycemia in the
PD group may have skewed the results [37, 38]. A recent
multicenter adult study in Belgium indicated that, in 1303
patients, mortality was higher (58% versus 43%) for AKI
patients in the RRT group than in conservative management
group despite correction for severity of illness [39]. Unfor-
tunately, clear evidence supporting or contraindicating the
useofCRRTinpediatricsislacking.Fortunately,throughthe
ppCRRT,thestudyofpediatricRRThasprogressedandmore
data emerges regarding the confounding variables associated
with the risks and beneﬁts of RRT. Some of these variables
are discussed below.
Opinion. As center-speciﬁc technical expertise expands, the
use of CRRT continues to also expand. Despite limited data
indicating itssuperiority overPD orIHD,the abilityto ﬁnely
control ﬂuid balance and electrolyte derangements makes
CRRT an ideal option in the hemodynamically unstable pa-
tient. Additionally, the ability to provide optimal nutrition
and deliver blood products and medicine while on CRRT
(without worrying excessively about ﬂuid shifts) is highly
desirable.Thetightcontrolofsuchdeliverablesisparamount
in the care of the critically ill pediatric patient and the pri-
mary reason why CRRTuseexpands. Institutional capability,
technical familiarity, and ability to obtain adequate vascular
access are barriers to its use, but eﬃcacy in unstable patients
is an attractive quality in this modality.
2.4. Controversies in Renal Replacement Therapy
Initiation ofRRT. Intheonlyrandomizedtrial ofearlyversus
late initiation of RRT in critically ill patients [40], 106 ven-
tilated, oliguric adults were randomized to either “high
volume-early” (initiation 8 hours after stratiﬁcation, 72–96L
hemoﬁltration in 24 hours), “low volume-early” (initiation
8 hours after stratiﬁcation, 24–36L hemoﬁltration in 24
hours), and “low volume-late” (initiation 36 hours after
stratiﬁcation, 24–36L hemoﬁltration in 24 hours) of CRRT.
Median duration of renal failure and 28-day survival were
not signiﬁcantly aﬀected by timing of initiation. However,
other data suggesting that early treatment is superior to late
treatment is encouraging in patients who developed AKI
following CPB [41–44]. There is also evidence suggesting
that early RRT aﬀords critically ill patients with a thera-
peutic strategy that goes beyond organ support. In other
words, RRT may a serve a more direct, therapeutic role in
ameliorating renal injury and improving the chances of
“renal recovery.” Renal recovery is variably deﬁned in the
literature, though most deﬁnitions used includethe criterion
of freedom from chronic RRT [45, 46]. The pediatric data
regarding timing of initiation is largely retrospective and
put into the context of triggers such as ﬂuid overload and
presence of sepsis.
Fluid Overload and CRRT. A retrospective study of 21 chil-
dren receiving RRTfor AKIsuggested that the degree ofﬂuid
overload (FO) at time of RRT initiation was signiﬁcantly
lower in survivors than in nonsurvivors (16.4% versus 34%)
[31]. In a larger study of 113 children with multiple-organ
dysfunction syndrome (MODS) started on CRRT, median
% FO was signiﬁcantly lower in survivors compared to
nonsurvivors (7.8% versus 15.1%), and mortality related to
FOwasindependentofseverityofillness [47].Anotherstudy
showed that, in 297 patients, % FO was again signiﬁcantly
lowerinsurvivorsversusnonsurvivors(12.5%versus23.0%)
[48]. In a prospective, uncontrolled, observational study
DiCarlo initiated CRRT for ten children with ARDS after
BMT regardless of presence of AKI and demonstrated an
80% survival rate [49]. Of the available retrospective evi-
dence, the mortality for children started on CRRT is 10–
57.1%.Inselectcenters,theuse ofPDaftercardiopulmonary
bypass during the immediate postoperative period is routine
[9]. The ppCRRT data suggests that a threshold may exist
for initiation of CRRT based on FO to improve mortality,
a threshold that appears to be independent of severity of
illness [7]. The threshold, 10–15%FO, however, has yet to be
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that children placed on CRRT for AKI have better outcomes
than those without such therapy.
Sepsis and CRRT. RRT for sepsis without AKI has been
attempted in adults, with the thought that RRT could
remove harmful circulating cytokines and inﬂammatory
mediators, but trials have been underpowered and results
regarding eﬃcacy have been varied. While many inﬂam-
matory mediators can be removed using RRT, speciﬁ-
cally CRRT, it is unknown how the amount removed
compares to the serum concentration of such mediators
and the signiﬁcance of certain levels. No studies of RRT
designed speciﬁcally to analyze its eﬃcacy in pediatric
sepsis, absent AKI, have been performed. A recent meta-
analysis of the major adult CRRT studies, comparing
the eﬃcacy of “intensive-dose” CRRT (>40mL/kg/hr) to
“less-intensive-dose” CRRT (<25mL/kg/hr), found no ben-
eﬁcial eﬀect of intensive dose on mortality in sepsis and AKI
[50]. While in vitro data continues to suggest that CRRTmay
oﬀer beneﬁt for immunomodulation in sepsis, clear clinical
data are lacking. Accordingly, in adults and in children,
the use of CRRT for immunomodulation is not currently
recommended [51].
Access. While adequate venous access is paramount to eﬀec-
tiveIHDor CRRT,PD conferstheadvantage of notrequiring
large vessel access. Catheter placement in children increases
risk for thrombosis and sclerosis, especially in the subclavian
veins, and may be detrimental to obtaining future access.
Data from the ppCRRT indicates that smaller catheters (5
and 7 French) and those placed in the femoral veins were
associated with shorter circuit lives than larger catheters and
those placed in the internal jugular veins [52]. Appropriate
cathetersizesandplacementaremutuallydependentandcan
vary, but a starting framework is shown in Table 2 [30].
Anticoagulation. The absence of a need for anticoagulation
is a major advantage for PD use. Heparin and citrate are the
major anticoagulants used in IHD and CRRT; registry data
reports equal circuit viability with both substances [53].
While citrate allows the patient to be free of heparin-in-
duced systemic anticoagulation, it may require several addi-
tional solutions to be run concurrently with the circuit:
anticoagulant dextrose solution A (ACD-A) [30]a n dac o n -
tinuous calcium infusion (infused through separate central
access) to prevent hypocalcemia which occurs when citrate
binds ionized calcium. Higher citrate clearances or lower
citrate delivery methods must be used to preventcitrate lock,
deﬁned as elevated serum total calcium but low serum ion-
ized calcium, which results from increased citrate buﬀering
of free calcium from decreased citrate metabolism.
Dose. The high dose of dialysis delivered in relation to time
is an advantage of IHD over PD and CRRT.Much of the data
regarding dose of RRT is retrospective and focuses on CRRT.
An initial study reported mortality lessened with larger doses
(≥35mL/kg/hr) than with smaller doses (20mL/kg/hr) [54].
However, a large recent study with meticulous documenta-
tion of actual doses received demonstrated no improvement
in kidney function or mortality outcome in adults receiving
high-intensity CRRT (35mL/kg/hr) versus low-intensity
CRRT (20mL/kg/hr) or intermittent hemodialysis [55]. The
few outcomes studies performed in pediatrics investigating
the eﬀects of RRT dosage and modality are retrospective.
The ppCRRT in 2007 demonstrated no diﬀerence in overall
outcomes based on modality or dose of CRRT used [56].
Modality of CRRT. As mentioned before, CRRT is oﬀered in
multiple modalities diﬀering based on primary principle of
ﬁltration used (convection or diﬀusion). While the ppCRRT
reported that 344 children on CRRT in 13 Centers in the
United States used CVVHD (venovenous hemodialysis)
(48%), CVVHDF (venovenous hemodiaﬁltration) (21%),
CVVHF (21%) (venovenous hemoﬁltration), and SCUF
(slow continuous ultraﬁltration) (1%), most centers only
oﬀer one modality [57]. As the names imply, the modalities
diﬀer based on the ability to incorporate one or both meth-
ods of ﬁltration (convection → ﬁltration based on hydro-
static pressure, diﬀusion → dialysis, particles move based
on concentration gradient). Some practitioners feel that
CVVHD is the optimal method by which to remove small
molecules in children, but this is most likely inﬂuenced by
site-speciﬁc preference (or availability) [58]. Though not yet
rigorously proven,ﬁlter life may also be aﬀected by modality.
In isolated studies, dialytic modes of CRRT oﬀer longer ﬁlter
survival (12 hours–48 hours) than purely ﬁltration modes
[59]. In the most recent ppCRRT data, more survivors had
convective RRT than nonsurvivors (61.0% versus 43.0%)
[48]. The lack of formal trials comparing modality in
pediatrics limits any formal recommendation on use in
relation to patient outcomes.
Outcomes. Limited prospective data is available to compare
morbidityandmortalitybetweenthethreedialyticmodes.In
adults, a study performed in a developing country analyzed
PD versus CRRT in infection-related AKI and found that
CRRT was signiﬁcantly superior to PD in all end-points
tested (reduction of creatinine, resolution of acidosis) [37].
In children, the data is quite limited, retrospective, and often
limited to speciﬁc disease processes, such as cardiopulmo-
nary bypass [60]. Data from the ppCRRT indicates 58%
survival for all children placed on RRT, although high mor-
tality rates (liver 69%, pulmonary 55%, and stem cell 55%)
seen in select transplant populations and children under 10
kilograms inﬂuence the data signiﬁcantly.
3.AKI,RenalAngina, and the Why
The use of renal replacement therapy in pediatrics continues
to blossom. It is uncertain whether the risks of dialysis, both
mechanical and technical, outweigh the perceived beneﬁts
(improved renal recovery or reduced mortality). At present,
the only proper way to answer the question would be to
conduct a prospective, randomized trial comparing the dif-
ferent RRT modalities to no invasive therapy, which would6 International Journal of Nephrology
be a trial loaded with ethical concerns. Further, if acute di-
alysis for AKI is actually beneﬁcial, the critical point of
intervention remains a mystery. Cardiac catheterization and
coronaryinterventiontherapyformyocardialinfarction were
optimized with the advent of troponins—tests made more
reliable when run in patients with risk factors and signs of
illness. Unfortunately, unlike chest pain, AKI does not hurt
and the symptoms of AKI without ﬂuid overload may be
quite subtle. The phenotype of AKI in its earliest stage
is unknown, which limits the applicability of biomarkers
and detection strategies, and treatment eﬀorts. Discovering
the equivalent of angina for chest pain and myocardial
infarction—renal angina—may strengthen biomarkerutility,
aid early AKI diagnosis, and possibly identify patients most
likely to beneﬁt from early renal replacement therapy [61].
Renal angina, deﬁned as the composite of risk factors (i.e.,
high blood pressure, smoking for heart disease and shock,
or sepsis for AKI) and subtle changes in renal function
(small changes in creatinine clearance or ﬂuid overload),
may identify patients who are at the highest risk. Prospective
trials comparing cohorts of patients and diﬀerent modalities
of RRT are needed to improve the delivery of care, and the
ppCRRT registry aims to reach this goal.
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